Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Adv Protein Chem Struct Biol ; 124: 225-274, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33632466

RESUMEN

Malaria is one of the most impacting public health problems in tropical and subtropical areas of the globe, with approximately 200 million cases worldwide annually. In the absence of an effective vaccine, rapid treatment is vital for effective malaria control. However, parasite resistance to currently available drugs underscores the urgent need for identifying new antimalarial therapies with new mechanisms of action. Among potential drug targets for developing new antimalarial candidates, protein kinases are attractive. These enzymes catalyze the phosphorylation of several proteins, thereby regulating a variety of cellular processes and playing crucial roles in the development of all stages of the malaria parasite life cycle. Moreover, the large phylogenetic distance between Plasmodium species and its human host is reflected in marked differences in structure and function of malaria protein kinases between the homologs of both species, indicating that selectivity can be attained. In this review, we describe the functions of the different types of Plasmodium kinases and highlight the main recent advances in the discovery of kinase inhibitors as potential new antimalarial drug candidates.


Asunto(s)
Antimaláricos/uso terapéutico , Sistemas de Liberación de Medicamentos , Malaria , Plasmodium/enzimología , Inhibidores de Proteínas Quinasas/uso terapéutico , Proteínas Quinasas/metabolismo , Proteínas Protozoarias , Antimaláricos/química , Humanos , Malaria/tratamiento farmacológico , Malaria/enzimología , Inhibidores de Proteínas Quinasas/química , Proteínas Protozoarias/antagonistas & inhibidores , Proteínas Protozoarias/metabolismo
2.
Adv Protein Chem Struct Biol ; 124: 275-309, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33632468

RESUMEN

The discovery and development of a new drug is a complex, time consuming and costly process that typically takes over 10 years and costs around 1 billion dollars from bench to market. This scenario makes the discovery of novel drugs targeting neglected tropical diseases (NTDs), which afflict in particular people in low-income countries, prohibitive. Despite the intensive use of High-Throughput Screening (HTS) in the past decades, the speed with which new drugs come to the market has remained constant, generating doubts about the efficacy of this approach. Here we review a few of the yeast-based high-throughput approaches that can work synergistically with parasite-based, in vitro, or in silico methods to identify and optimize novel antiparasitic compounds. These yeast-based methods range from HTP screens to identify novel hits against promising parasite kinase targets to the identification of potential antiparasitic kinase inhibitors extracted from databases of yeast chemical genetic screens.


Asunto(s)
Descubrimiento de Drogas , Enfermedades Desatendidas , Inhibidores de Proteínas Quinasas , Proteínas Quinasas , Saccharomyces cerevisiae , Evaluación Preclínica de Medicamentos , Humanos , Enfermedades Desatendidas/tratamiento farmacológico , Enfermedades Desatendidas/enzimología , Enfermedades Desatendidas/genética , Inhibidores de Proteínas Quinasas/química , Inhibidores de Proteínas Quinasas/uso terapéutico , Proteínas Quinasas/genética , Proteínas Quinasas/metabolismo , Saccharomyces cerevisiae/enzimología , Saccharomyces cerevisiae/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA